menu
    • menu

    Find Dapagliflozin manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 67
    Dapagliflozin

    Virtual Booth

    Contact Supplier

    Metrochem Dapagliflozin

    Virtual Booth

    Contact Supplier

    CHSD Dapagliflozin

    Virtual Booth

    Contact Supplier

    DRL Dapagliflozin

    Virtual Booth

    Contact Supplier

    Dapagliflozin

    Virtual Booth

    Contact Supplier

    Dapagliflozin

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 461432-26-8, Bms-512148, Forxiga, Bms 512148, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol, Dagagflozin
    Molecular Formula
    C21H25ClO6
    Molecular Weight
    408.9  g/mol
    InChI Key
    JVHXJTBJCFBINQ-ADAARDCZSA-N
    FDA UNII
    1ULL0QJ8UC
    Dapagliflozin
    Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.
    Dapagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of dapagliflozin is as a Sodium-Glucose Transporter 2 Inhibitor.
    1 2D Structure

    Dapagliflozin

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
    2.1.2 InChI
    InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
    2.1.3 InChI Key
    JVHXJTBJCFBINQ-ADAARDCZSA-N
    2.1.4 Canonical SMILES
    CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
    2.1.5 Isomeric SMILES
    CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    1ULL0QJ8UC
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

    2. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol

    3. Bms 512148

    4. Bms-512148

    5. Bms512148

    6. Farxiga

    7. Forxiga

    2.3.2 Depositor-Supplied Synonyms

    1. 461432-26-8

    2. Bms-512148

    3. Forxiga

    4. Bms 512148

    5. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

    6. Dagagflozin

    7. (1s)-1,5-anhydro-1-c-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-d-glucitol

    8. 1ull0qj8uc

    9. Chembl429910

    10. Chebi:85078

    11. Lyn-045

    12. Dapagliflozin [usan:inn]

    13. (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol

    14. (2s,3r,4r,5s,6r)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol

    15. Bms512148

    16. Forxiga (tn)

    17. Chembl3125458

    18. D-glucitol, 1,5-anhydro-1-c-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1s)-

    19. (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

    20. Dapagliflozin [usan]

    21. Unii-1ull0qj8uc

    22. Bms5121458

    23. S1548_selleck

    24. C-aryl Glucoside, 6

    25. Dapagliflozin [mi]

    26. Dapagliflozin [inn]

    27. Dapagliflozin (usan/inn)

    28. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2h-pyran-3,4,5-triol

    29. Dapagliflozin [vandf]

    30. Schembl157820

    31. Dapagliflozin [who-dd]

    32. Gtpl4594

    33. Bdbm20880

    34. Dtxsid20905104

    35. Ex-a005

    36. Bcpp000265

    37. Dapagliflozin [orange Book]

    38. Amy18541

    39. Zinc3819138

    40. Bdbm50448923

    41. Mfcd13182359

    42. S1548

    43. Qternmet Component Dapaglifozin

    44. Akos005145763

    45. Dapagliflozin Component Qternmet

    46. Bcp9000583

    47. Bl-0052

    48. Ccg-229917

    49. Cs-0781

    50. Db06292

    51. Ex-7214

    52. Ncgc00250402-09

    53. Ac-24699

    54. Bd164346

    55. Hy-10450

    56. Qternmet Xr Component Dapagliflozin

    57. Dapagliflozin Component Of Qternmet Xr

    58. A25150

    59. C22193

    60. D08897

    61. 432d268

    62. Q409898

    63. J-500392

    64. Brd-k58160573-001-01-3

    65. Brd-k58160573-001-05-4

    66. 1-[3-(beta-d-glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene

    67. (1s)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-d-glucitol

    68. (2s, 3r, 4r, 5s, 6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol

    69. (2s,3r,4r,5s,6r)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2h-pyran-3,4,5-triol

    70. (2s,3r,4r,5s,6r)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2h-pyran-3,4,5-triol;bms-512148

    71. (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 408.9 g/mol
    Molecular Formula C21H25ClO6
    XLogP32.3
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count6
    Exact Mass408.1339662 g/mol
    Monoisotopic Mass408.1339662 g/mol
    Topological Polar Surface Area99.4 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity472
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameFarxiga
    PubMed HealthDapagliflozin (By mouth)
    Drug ClassesAntidiabetic
    Drug LabelDapagliflozin is described chemically as D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1). The empirical formula is C21H25ClO6C3H8O2H2O and the molecular weig...
    Active IngredientDapagliflozin
    Dosage FormTablet
    RouteOral
    Strength5mg; 10mg
    Market StatusPrescription
    CompanyAstrazeneca Ab

    2 of 2  
    Drug NameFarxiga
    PubMed HealthDapagliflozin (By mouth)
    Drug ClassesAntidiabetic
    Drug LabelDapagliflozin is described chemically as D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1). The empirical formula is C21H25ClO6C3H8O2H2O and the molecular weig...
    Active IngredientDapagliflozin
    Dosage FormTablet
    RouteOral
    Strength5mg; 10mg
    Market StatusPrescription
    CompanyAstrazeneca Ab

    4.2 Drug Indication

    Dapagliflozin is indicated to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.

    FDA Label

    Forxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

    - as monotherapy when metformin is considered inappropriate due to intolerance.

    - in addition to other medicinal products for the treatment of type 2 diabetes.

    For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied.

    Heart failure

    - Forxiga is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

    Chronic kidney disease

    - Forxiga is indicated in adults for the treatment of chronic kidney disease.

    Type 2 diabetes mellitus

    Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

    - as monotherapy when metformin is considered inappropriate due to intolerance.

    - in addition to other medicinal products for the treatment of type 2 diabetes.

    For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 and 5. 1.

    Heart failure

    Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

    Chronic kidney disease

    Edistride is indicated in adults for the treatment of chronic kidney disease.

    Treatment of chronic kidney disease

    Prevention of cardiovascular events in patients with chronic heart failure

    Treatment of type I diabetes mellitus

    Treatment of type II diabetes mellitus

    Treatment of ischaemic heart disease

    Treatment of Coronavirus disease 2019 (COVID-19)

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Dapagliflozin inhibits the sodium-glucose contransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose resorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.

    5.2 MeSH Pharmacological Classification

    Sodium-Glucose Transporter 2 Inhibitors

    Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. (See all compounds classified as Sodium-Glucose Transporter 2 Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    DAPAGLIFLOZIN
    5.3.2 FDA UNII
    1ULL0QJ8UC
    5.3.3 Pharmacological Classes
    Sodium-Glucose Transporter 2 Inhibitors [MoA]; Sodium-Glucose Cotransporter 2 Inhibitor [EPC]
    5.4 ATC Code

    A10BK01

    A10BK01

    A10BK01

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    A - Alimentary tract and metabolism

    A10 - Drugs used in diabetes

    A10B - Blood glucose lowering drugs, excl. insulins

    A10BK - Sodium-glucose co-transporter 2 (sglt2) inhibitors

    A10BK01 - Dapagliflozin

    5.5 Absorption, Distribution and Excretion

    Absorption

    Oral dapagliflozin reaches a maximum concentration within 1 hour of administration when patients have been fasting. When patients have consumed a high fat meal, the time to maximum concentration increases to 2 hours and the maximum concentration decreases by half though a dose adjustment is not necessary. Oral dapagliflozin is 78% bioavailable.

    Route of Elimination

    75.2% of dapagliflozin is recovered in the urine with 1.6% of the dose unchanged by metabolism. 21% of the dose is excreted in the feces with 15% of the dose unchanged by metabolism.

    Volume of Distribution

    118L.

    Clearance

    Oral plasma clearance was 4.9 mL/min/kg, and renal clearance was 5.6 mL/min.

    5.6 Metabolism/Metabolites

    Dapagliflozin is primarily glucuronidated to become the inactive 3-O-glucuronide metabolite(60.7%). Dapagliflozin also produces another minor glucuronidated metabolite(5.4%), a de-ethylated metabolite(<5%), and a hydroxylated metabolite(<5%). Metabolism of dapagliflozin is mediated by cytochrome p-450(CYP)1A1, CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP3A4, uridine diphosphate glucuronyltransferase(UGT)1A9, UGT2B4, and UGT2B7. Glucuronidation to the major metabolite is mediated by UGT1A9.

    5.7 Biological Half-Life

    13.8h.

    5.8 Mechanism of Action

    Dapagliflozin inhibits the sodium-glucose contransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose resorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine. This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.

    API SUPPLIERS

    read-more
    read-more

    01

    Polpharma

    Poland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Booth #321
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEuropean CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Contact Supplier Contact Supplier
    Flag Poland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-05-23

    Pay. Date : 2016-12-08

    DMF Number : 30555

    Submission : 2016-05-12

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 305MF10084

    Registrant's Address : 19 Pellinska Str. 83-200 Starogard Gdanski POLAND

    Initial Date of Registration : 2023-07-19

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Hiple Co., Ltd.

    Registration Date : 2019-09-26

    Registration Number : Su30-3-ND

    Manufacturer Name : Zakłady Farmaceutyczne Polpharma SA

    Manufacturer Address : 19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

     VMF ASMF, CA arrow-down
    ✖
    Available Reg Filing : ASMF, CA
    AUDIT arrow-down
    Polpharma CB

    02

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-04-17

    Pay. Date : 2017-03-20

    DMF Number : 30729

    Submission : 2016-12-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-28

    Valid Till : 2025-11-30

    Written Confirmation Number : WC-0390

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 55111-987

    Start Marketing Date : 2016-12-30

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Pamire Co., Ltd.

    Registration Date : 2019-04-03

    Registration Number : Su574-13-ND

    Manufacturer Name : Dr. Reddy's Laboratories Limited

    Manufacturer Address : CTO-SEZ Process Unit-01, Sector No.'s 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey No.'s 57 to 58, 60, 72 to 73, 76 to 77 & 80, Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District 532409, Andhra Pradesh, India

     VMF ASMF, CD... arrow-down
    ✖
    Available Reg Filing : ASMF, CDMF
    AUDIT arrow-down
    Dr Reddy Company Banner

    03

    Metrochem API Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Booth #1J-48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36608

    Submission : 2022-02-10

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2025-043 - Rev 00

    Issue Date : 2025-08-06

    Type : Chemical

    Substance Number : 3137

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 42765-042

    Start Marketing Date : 2022-02-11

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Sam-O Pharmaceutical Co., Ltd.

    Registration Date : 2025-01-13

    Registration Number : Su207-70-ND

    Manufacturer Name : Metrochem API Private Limited

    Manufacturer Address : Unit-IV, Plot No. 34B, 40B & 60B, JN Pharma City, Thanam Village, Parawada Mandal, Visakhapatnam District, Andhra Pradesh, 531021, India.

     VMF Others AUDIT
    Metrochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Shandong Chenghui Shuangda Pharmac...

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Booth #1C-08
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothChina’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2024-09-23

    Valid Till : 2027-09-22

    Written Confirmation Number : SD240069

    Address of the Firm :

    NDC KDMF VMF Others AUDIT arrow-down
    Shandong Chenghui Shuangda Pharmaceutical

    05

    Neuland Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Booth #2G10
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    Neuland

    06

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Interphex
    Booth #2158
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Aarti Pharmalabs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI North America
    Booth #1636
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
    Aarti Industries Company Banner

    08

    Ami Lifesciences Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38009

    Submission : 2023-02-23

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    AMI Lifesciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    HRV Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothHRV Pharma - Market Expansion Leader in Pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF AU arrow-down
    ✖
    Available Reg Filing : AU
    AUDIT
    HRV Global Life Sciences

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Octavius Pharma Pvt. Ltd

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Octavius Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - TABLET;ORAL - 10MG

    USFDA APPLICATION NUMBER - 202293

    read-more

    DOSAGE - TABLET;ORAL - 5MG

    USFDA APPLICATION NUMBER - 202293

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Topical

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 461432-26-8 / Dapagliflozin API manufacturers, exporters & distributors?

    Dapagliflozin manufacturers, exporters & distributors 1

    32

    PharmaCompass offers a list of Dapagliflozin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dapagliflozin manufacturer or Dapagliflozin supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dapagliflozin manufacturer or Dapagliflozin supplier.

    API | Excipient name

    Dapagliflozin

    Synonyms

    461432-26-8, Bms-512148, Forxiga, Bms 512148, (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol, Dagagflozin

    Cas Number

    461432-26-8

    Unique Ingredient Identifier (UNII)

    1ULL0QJ8UC

    About Dapagliflozin

    Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut.

    Forxiga (TN) Manufacturers

    A Forxiga (TN) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Forxiga (TN), including repackagers and relabelers. The FDA regulates Forxiga (TN) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Forxiga (TN) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Forxiga (TN) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Forxiga (TN) Suppliers

    A Forxiga (TN) supplier is an individual or a company that provides Forxiga (TN) active pharmaceutical ingredient (API) or Forxiga (TN) finished formulations upon request. The Forxiga (TN) suppliers may include Forxiga (TN) API manufacturers, exporters, distributors and traders.

    click here to find a list of Forxiga (TN) suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Forxiga (TN) USDMF

    A Forxiga (TN) DMF (Drug Master File) is a document detailing the whole manufacturing process of Forxiga (TN) active pharmaceutical ingredient (API) in detail. Different forms of Forxiga (TN) DMFs exist exist since differing nations have different regulations, such as Forxiga (TN) USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Forxiga (TN) DMF submitted to regulatory agencies in the US is known as a USDMF. Forxiga (TN) USDMF includes data on Forxiga (TN)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Forxiga (TN) USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Forxiga (TN) suppliers with USDMF on PharmaCompass.

    Forxiga (TN) JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Forxiga (TN) Drug Master File in Japan (Forxiga (TN) JDMF) empowers Forxiga (TN) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Forxiga (TN) JDMF during the approval evaluation for pharmaceutical products. At the time of Forxiga (TN) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Forxiga (TN) suppliers with JDMF on PharmaCompass.

    Forxiga (TN) KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Forxiga (TN) Drug Master File in Korea (Forxiga (TN) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Forxiga (TN). The MFDS reviews the Forxiga (TN) KDMF as part of the drug registration process and uses the information provided in the Forxiga (TN) KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Forxiga (TN) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Forxiga (TN) API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Forxiga (TN) suppliers with KDMF on PharmaCompass.

    Forxiga (TN) CEP

    A Forxiga (TN) CEP of the European Pharmacopoeia monograph is often referred to as a Forxiga (TN) Certificate of Suitability (COS). The purpose of a Forxiga (TN) CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Forxiga (TN) EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Forxiga (TN) to their clients by showing that a Forxiga (TN) CEP has been issued for it. The manufacturer submits a Forxiga (TN) CEP (COS) as part of the market authorization procedure, and it takes on the role of a Forxiga (TN) CEP holder for the record. Additionally, the data presented in the Forxiga (TN) CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Forxiga (TN) DMF.

    A Forxiga (TN) CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Forxiga (TN) CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Forxiga (TN) suppliers with CEP (COS) on PharmaCompass.

    Forxiga (TN) WC

    A Forxiga (TN) written confirmation (Forxiga (TN) WC) is an official document issued by a regulatory agency to a Forxiga (TN) manufacturer, verifying that the manufacturing facility of a Forxiga (TN) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Forxiga (TN) APIs or Forxiga (TN) finished pharmaceutical products to another nation, regulatory agencies frequently require a Forxiga (TN) WC (written confirmation) as part of the regulatory process.

    click here to find a list of Forxiga (TN) suppliers with Written Confirmation (WC) on PharmaCompass.

    Forxiga (TN) NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Forxiga (TN) as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Forxiga (TN) API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Forxiga (TN) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Forxiga (TN) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Forxiga (TN) NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Forxiga (TN) suppliers with NDC on PharmaCompass.

    Forxiga (TN) GMP

    Forxiga (TN) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Forxiga (TN) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Forxiga (TN) GMP manufacturer or Forxiga (TN) GMP API supplier for your needs.

    Forxiga (TN) CoA

    A Forxiga (TN) CoA (Certificate of Analysis) is a formal document that attests to Forxiga (TN)'s compliance with Forxiga (TN) specifications and serves as a tool for batch-level quality control.

    Forxiga (TN) CoA mostly includes findings from lab analyses of a specific batch. For each Forxiga (TN) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Forxiga (TN) may be tested according to a variety of international standards, such as European Pharmacopoeia (Forxiga (TN) EP), Forxiga (TN) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Forxiga (TN) USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search